Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
Samsung Biologics and AstraZeneca continues their strategic biopharmaceutical manufacturing collaboration to manufacturer AstraZeneca’s COVID-19 long-acting antibody (LAAB) combination, AZD7442, and will start to manufacture a cancer immunotherapy product from next year following an expanded deal this year in May 2021. With additional treatments manufactured, the value of the agreement boosted to approximately $380 million up from the initial $331 million.
AZD7442 is a combination of two LAABs being developed for the prevention and treatment of COVID-19. AZD7442 is the first LAAB to receive an EUA from the US Food and Drug Administration (FDA) for COVID-19 prevention and it has received authorizations from the US, France, Italy, and Bahrain. It is to provide additional protection for those considered at increased risk of an inadequate response to a COVID-19 vaccine.
“Over the past year Samsung Biologics has been a highly capable and collaborative partner on our novel COVID-19 long-acting antibody combination. We are excited about expanding our work together into cancer immunotherapy and about laying the foundation for continued growth of our collaboration in the years ahead,” Pam Cheng, Executive Vice President, Global Operations and IT, AstraZeneca said.
John Rim, CEO of Samsung Biologics said, “We are delighted to continue expanding our strategic collaboration with AstraZeneca, a valuable partner we have witnessed first-hand to have a strong commitment to saving lives of patients.”